Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) Latest Company News

Oct 20, 2026, 09:07 UTC
Haisco Pharmaceutical Group forecast net profit attributable to shareholders of RMB 1.32 billion to RMB 1.4 billion for the first three quarters of 2026, up 297.02% to 321.08% year over year, and adjusted net profit of RMB 1.22 billion to RMB 1.3 billion, up 250.27% to 273.24%.
Source:
- finance.sina.cn
Oct 11, 2026, 07:46 UTC
Haisco Pharmaceutical Group announced the election of Wang Junmin as chairman of its sixth board and the appointments of Yan Pangke as general manager, Wang Meng as deputy general manager and board secretary, and Duan Peng as financial controller.
Source:
- finance.sina.cn
Sep 27, 2026, 07:40 UTC
China's National Medical Products Administration Center for Drug Evaluation included Haisco Pharmaceutical's innovative drug HSK42360-Na tablets in the Breakthrough Therapy List on September 23, 2026, for BRAF V600-mutant recurrent or progressive high-grade glioma.
Source:
Sep 8, 2026, 10:12 UTC
Haisco Pharmaceutical shareholder Fan Xiulian released a pledge of 2.36 million shares on September 7, 2026.
Source:
- finance.sina.cn
Sep 8, 2026, 10:12 UTC
Haisco Pharmaceutical's controlling shareholder Wang Junmin extended the pledge of 9 million shares to China Merchants Securities, with the pledge maturity postponed to September 8, 2027.
Source:
- finance.sina.cn
Aug 26, 2026, 18:02 UTC
Haisco licensed its preclinical immunology asset to Sentivera in a deal valued at more than $1.5 billion.
Source:
- pharmexec.com
Aug 26, 2026, 10:27 UTC
Haisco Pharmaceutical proposed a cash dividend of 5.26 yuan per 10 shares (tax included) to all shareholders, based on a base of 1.141 billion shares.
Source:
- finance.sina.cn
Aug 26, 2026, 10:27 UTC
Haisco Pharmaceutical announced its 2026 first-half results: revenue of 3.096 billion yuan, up 54.71% year-on-year; net profit attributable to shareholders of 851 million yuan, up 426.98% year-on-year.
Source:
- finance.sina.cn
- finance.sina.cn
Aug 12, 2026, 07:40 UTC
Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule drug HSK60002, intended for inflammatory diseases.
Source:
- finance.sina.cn
Aug 11, 2026, 11:03 UTC
Haisco Pharmaceutical Group shareholder Fan Xiulian pledged 29 million shares on August 10, 2026, as collateral for a loan, with the pledge maturing on August 9, 2029.
Source:
- finance.sina.cn
Aug 6, 2026, 08:07 UTC
Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule analgesic drug HSK51155, intended for migraine treatment.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 23, 2026, 03:47 UTC
Haisco announced that its Class 1 innovative drug, Succinate Sipukepan Tablets, received marketing approval from China's National Medical Products Administration for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitor therapy.
Source:
- finance.sina.cn
Jul 23, 2026, 02:32 UTC
China's National Medical Products Administration approved two innovative drugs through priority review: Takeda's ORZEYFUL for narcolepsy and Haisco Pharmaceutical's suplatast tosilate for PNH.
Source:
- finance.sina.cn
Jun 22, 2026, 11:48 UTC
Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.
Source:

002653.SZ

Haisco Pharmaceutical Group forecast net profit attributable to shareholders of RMB 1.32 billion to RMB 1.4 billion for the first three quarters of 2026, up 297.02% to 321.08% year over year, and adjusted net profit of RMB 1.22 billion to RMB 1.3 billion, up 250.27% to 273.24%.

Haisco Pharmaceutical Group announced the election of Wang Junmin as chairman of its sixth board and the appointments of Yan Pangke as general manager, Wang Meng as deputy general manager and board secretary, and Duan Peng as financial controller.

China's National Medical Products Administration Center for Drug Evaluation included Haisco Pharmaceutical's innovative drug HSK42360-Na tablets in the Breakthrough Therapy List on September 23, 2026, for BRAF V600-mutant recurrent or progressive high-grade glioma.

Haisco Pharmaceutical shareholder Fan Xiulian released a pledge of 2.36 million shares on September 7, 2026.

Haisco Pharmaceutical's controlling shareholder Wang Junmin extended the pledge of 9 million shares to China Merchants Securities, with the pledge maturity postponed to September 8, 2027.

Haisco licensed its preclinical immunology asset to Sentivera in a deal valued at more than $1.5 billion.

Haisco Pharmaceutical proposed a cash dividend of 5.26 yuan per 10 shares (tax included) to all shareholders, based on a base of 1.141 billion shares.

Haisco Pharmaceutical announced its 2026 first-half results: revenue of 3.096 billion yuan, up 54.71% year-on-year; net profit attributable to shareholders of 851 million yuan, up 426.98% year-on-year.

Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule drug HSK60002, intended for inflammatory diseases.

Haisco Pharmaceutical Group shareholder Fan Xiulian pledged 29 million shares on August 10, 2026, as collateral for a loan, with the pledge maturing on August 9, 2029.

Haisco Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed oral small-molecule analgesic drug HSK51155, intended for migraine treatment.

Haisco announced that its Class 1 innovative drug, Succinate Sipukepan Tablets, received marketing approval from China's National Medical Products Administration for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitor therapy.

China's National Medical Products Administration approved two innovative drugs through priority review: Takeda's ORZEYFUL for narcolepsy and Haisco Pharmaceutical's suplatast tosilate for PNH.

Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.